Metagenomi Therapeutics, Inc. filed a current report on Form 8-K with the SEC on September 22, 2026, disclosing a September 2026 corporate presentation under Regulation FD as Exhibit 99.1.
Key Highlights
- Filing type: Current report disclosing a corporate presentation under Item 7.01, Regulation FD Disclosure
- Event date: September 21, 2026, is the date of the earliest event reported
- Exhibit: The September 2026 corporate presentation is furnished as Exhibit 99.1
- Not "filed": The information in Item 7.01 and Exhibit 99.1 is furnished and "shall not be deemed filed" for purposes of Section 18 of the Exchange Act
- Emerging growth company: The registrant is designated an emerging growth company and has elected not to use the extended transition period for new or revised financial accounting standards
- Signatory: The report was signed by Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer
Metagenomi Therapeutics Furnishes Corporate Presentation Under Regulation FD
Metagenomi Therapeutics, Inc. (NASDAQ:MGX), headquartered at 5959 Horton Street, 7th Floor, Emeryville, California 94608, submitted a current report on Form 8-K dated September 21, 2026. The filing is made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company's common stock, with a par value of $0.0001 per share, is registered on the Nasdaq Global Select Market under the trading symbol MGX.
According to the filing, under Item 7.01, the company furnished its September 2026 corporate presentation as Exhibit 99.1, incorporating it by reference into the current report. The filing explicitly states that the information contained in Item 7.01, including Exhibit 99.1, "is being furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended," and is not subject to the liabilities of that section. The filing further notes that the furnished information "shall not be deemed incorporated by reference in any filing" under the Securities Act of 1933 or the Exchange Act, except where expressly set forth by specific reference.
The registrant disclosed it qualifies as an emerging growth company under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act, and has elected not to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act. The report was signed by Jian Irish, Ph.D., M.B.A., in the capacity of President and Chief Executive Officer, on September 21, 2026.
What Was Disclosed
Metagenomi Therapeutics furnished its September 2026 corporate presentation to the SEC under Regulation FD. The presentation is attached as Exhibit 99.1, and the company noted it is furnished, not filed, limiting its liability under Section 18 of the Exchange Act.



Please wait processing your request...